Can a drug combo turn inoperable esophageal cancer into a surgical target?
NCT ID NCT07549100
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a combination of tislelizumab (an immunotherapy) and chemotherapy can shrink advanced esophageal tumors enough to allow surgery. Thirty patients with initially inoperable cancer will receive 2-4 cycles of the drug combo, then be reassessed for surgery. The main goal is to see how many become eligible for surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tislelizumab plus chemotherapy (albumin-bound paclitaxel and cisplatin or carboplatin)
- What this could lead to
- If successful, this approach could allow more patients with advanced esophageal cancer to undergo potentially curative surgery.
- What could go wrong
- This is a small, early-phase study with only 30 participants and no comparison group. The combination may cause significant side effects, and not all tumors may shrink enough for surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shandong Provincial Hospital
RECRUITINGJinan, Shandong, 250000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.